GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Statera BioPharma Inc (OTCPK:STAB) » Definitions » Net Current Asset Value

Statera BioPharma (Statera BioPharma) Net Current Asset Value : $-0.43 (As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Statera BioPharma Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Statera BioPharma's net current asset value per share for the quarter that ended in Sep. 2022 was $-0.43.

The historical rank and industry rank for Statera BioPharma's Net Current Asset Value or its related term are showing as below:

STAB's Price-to-Net-Current-Asset-Value is not ranked *
in the Biotechnology industry.
Industry Median: 3.9
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

Statera BioPharma Net Current Asset Value Historical Data

The historical data trend for Statera BioPharma's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Statera BioPharma Net Current Asset Value Chart

Statera BioPharma Annual Data
Trend Dec19 Dec20 Dec21
Net Current Asset Value
-0.16 -0.15 -0.52

Statera BioPharma Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -0.33 -0.52 -0.29 -0.38 -0.43

Competitive Comparison of Statera BioPharma's Net Current Asset Value

For the Biotechnology subindustry, Statera BioPharma's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Statera BioPharma's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Statera BioPharma's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Statera BioPharma's Price-to-Net-Current-Asset-Value falls into.



Statera BioPharma Net Current Asset Value Calculation

Statera BioPharma's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2021 is calculated as

Net Current Asset Value Per Share(A: Dec. 2021 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(4.155-22.676-0.061-0)/35.4841
=-0.52

Statera BioPharma's Net Current Asset Value (NCAV) per share for the quarter that ended in Sep. 2022 is calculated as

Net Current Asset Value Per Share(Q: Sep. 2022 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(1.222-22.917-0.073-0)/50.7447
=-0.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Statera BioPharma  (OTCPK:STAB) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Statera BioPharma Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Statera BioPharma's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Statera BioPharma (Statera BioPharma) Business Description

Traded in Other Exchanges
N/A
Address
4333 Corbett Drive, Suite 1082, Fort Collins, CO, USA, 80525
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction.
Executives
Satishchandran Chandrasekhar director 167 CARMELA COURT, JUPITER FL 33478
Taunia Markvicka director, officer: Chief Operating Officer 2537 RESEARCH BOULEVARD, SUITE 201, FORT COLLINS CO 80526
Robert Buckheit officer: Chief Technology Officer C/O CYTOCOM INC., 2537 RESEARCH BLVD, SUITE 201, FORT COLLINS CO 80526
Mcavoy Cozette M. officer: Chief Legal Officer 2537 RESEARCH BOULEVARD, SUITE 201, FORT COLLINS CO 80526
Michael K Handley director, officer: President and CEO 9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Clifford Selsky officer: Chief Medical Officer 2537 RESEARCH BOULERVARD, SUITE 201, FORT COLLINS CO 80526
Peter Aronstam officer: Chief Financial Officer 2537 RESEARCH BLVD, SUITE 201, FORT COLLINS CO 80526
Steve K Barbarick director TRACTOR SUPPLY COMPANY, 5401 VIRGINIA WAY, BRENTWOOD TN 37027
Christopher Zosh officer: Vice President of Finance C/O CLEVELAND BIOLABS, INC., 73 HIGH STREET, BUFFALO NY 14203
Ivan Fedyunin director 73 HIGH STREET, BUFFALO NY 14203
John Edward Szydlo officer: Principal Financial Officer 73 HIGH STREET, BUFFALO NY 14203
Alexander Andryushechkin director 73 HIGH STREET, BUFFALO NY 14203
Daniil Talyanskiy director 73 HIGH STREET, BUFFALO NY 14203
Lea Verny director 73 HIGH STREET, BUFFALO NY 14203
Alexey Nechaev director 73 HIGH STREET, BUFFALO NY 14203

Statera BioPharma (Statera BioPharma) Headlines

From GuruFocus